PPT-MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,

VTE death for rivaroxaban vs enoxaparin 27 vs 27 p for noninferiority 00025 at 35 days 44 vs 57 p 002 Clinically relevant bleeding at 10 days 28 vs 12 at

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/932464" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "MAGELLAN Primary efficacy endpoint at 1..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.